UNH is converting repricing and benefit cuts into a lower medical cost ratio faster than the Street modeled, and a better-than-feared 2027 Medicare Advantage rate sets up a second year of earnings recovery. At about 19x 2026 guidance, the stock still sits roughly 18% below its July high.
UnitedHealth Group is one of the largest private health insurers and provides medical benefits to about 51 million members globally, including 1 million outside the US as of December 2025. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in medical insurance. Along with its…
www.unitedhealthgroup.com- 1Q3 2026 results on Oct 13 (before the open, 8:00 a.m. ET call): a reaffirmed or raised $19.50-$20.00 guide and a stable medical care ratio.
- 2MA open enrollment from Oct 15 to Dec 7, and the 2027 plan changes, which test whether the exits and benefit cuts hold margin.
- 3Initial 2027 guidance with the Q4 report in January 2027, against roughly $23 consensus EPS.
- 1Q2 included about $860M of favorable prior-period reserve development, so underlying margin gains may be smaller than the headline (per Financial Report Insi…
- 2The company said commercial margins are not expanding as planned, because of aggressive provider billing and GLP-1 and specialty drug spend.
- 3CMS payment is still growing slower than cost trend, and shrinking MA enrollment with about 3% revenue growth makes 2027 EPS growth depend on margin execution.
Read the Full Thesis
- Oct 13, 2026 · Price 376.55
Weekly check-in: Strengthened. Q3 beat and raised the guide, but reserve releases and commercial costs persist The first checkpoint, Q3 on Oct 13, cleared the bar. Per the Q3 release, adjusted EPS was $4.69 against about $4.14 expected per LSEG, and the 2026 adjusted guide moved to at least $20.50 from $19.50-$20.00. The medical care ratio was 88.4% versus 89.9% a year earlier, and management now expects MA margins near the top of its 2% to 4% range, which supports the margin-recovery thesis. Two cautions remain. The MCR again included favorable prior-period reserve development, and commercial costs are running above 11%, which management says will stretch out margin recovery. The stock opened near $398, faded through the call, and traded around $377.
- Oct 20, 2026 · Price 419.7
Weekly check-in: On Track. No new fundamentals since Oct 13; shares re-rated toward the target, narrowing the discount Nothing new came from the company this week. Open enrollment began Oct 15, and the next company update is the Q4 report, with 2027 guidance, due Jan 12, 2027 per Yahoo. The change is price: shares closed near $420 on Oct 20, up from the high-$370s to $389 around the Q3 print. That erodes the 'still underpriced' framing. The case's 'about 18% below the July high' is now closer to 9% (July high $461.62), and the entry level of $375 is well behind the stock. The earnings evidence (guide of at least $20.50, MCR 88.4%) is unchanged and still supportive.
Disagree? Make the opposite case with your own levels. Both get scored, so the debate gets a winner.
Copy it into your own account, adjust it to your view, and get an alert when the price reaches its levels.